These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 29482434)

  • 1. An index of fatal toxicity for new psychoactive substances.
    King LA; Corkery JM
    J Psychopharmacol; 2018 Jul; 32(7):793-801. PubMed ID: 29482434
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An index of fatal toxicity for drugs of misuse.
    King LA; Corkery JM
    Hum Psychopharmacol; 2010 Mar; 25(2):162-6. PubMed ID: 20104506
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 4,4'-DMAR: chemistry, pharmacology and toxicology of a new synthetic stimulant of abuse.
    Coppola M; Mondola R
    Basic Clin Pharmacol Toxicol; 2015 Jul; 117(1):26-30. PubMed ID: 25819702
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel Psychoactive Substances and Trends of Abuse.
    Rivera JV; Vance EG; Rushton WF; Arnold JK
    Crit Care Nurs Q; 2017; 40(4):374-382. PubMed ID: 28834859
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of novel psychoactive drug use in Sweden based on laboratory analysis--initial experiences from the STRIDA project.
    Helander A; Beck O; Hägerkvist R; Hultén P
    Scand J Clin Lab Invest; 2013 Aug; 73(5):400-6. PubMed ID: 23692208
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Profile, effects, and toxicity of novel psychoactive substances: A systematic review of quantitative studies.
    Assi S; Gulyamova N; Ibrahim K; Kneller P; Osselton D
    Hum Psychopharmacol; 2017 May; 32(3):. PubMed ID: 28631432
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessing the toxicological significance of new psychoactive substances in fatalities.
    Elliott S; Sedefov R; Evans-Brown M
    Drug Test Anal; 2018 Jan; 10(1):120-126. PubMed ID: 28635164
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical toxicity following analytically confirmed use of the synthetic cannabinoid receptor agonist MDMB-CHMICA. A report from the Identification Of Novel psychoActive substances (IONA) study.
    Hill SL; Najafi J; Dunn M; Acheampong P; Kamour A; Grundlingh J; Blain PG; Thomas SH
    Clin Toxicol (Phila); 2016 Sep; 54(8):638-43. PubMed ID: 27251903
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patterns of Acute Toxicity Associated with New Psychoactive Substances.
    Hill SL; Dargan PI
    Handb Exp Pharmacol; 2018; 252():475-494. PubMed ID: 29896654
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The drug situation in Europe: an overview of data available on illicit drugs and new psychoactive substances from European monitoring in 2015.
    Mounteney J; Griffiths P; Sedefov R; Noor A; Vicente J; Simon R
    Addiction; 2016 Jan; 111(1):34-48. PubMed ID: 26419329
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Seizures as a complication of recreational drug use: Analysis of the Euro-DEN Plus data-set.
    Wolfe CE; Wood DM; Dines A; Whatley BP; Yates C; Heyerdahl F; Hovda KE; Giraudon I; Dargan PI;
    Neurotoxicology; 2019 Jul; 73():183-187. PubMed ID: 30974132
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mortality attributed to misuse of psychoactive drugs, 1979-88.
    Wysowski DK; Schober SE; Wise RP; Kopstein A
    Public Health Rep; 1993; 108(5):565-70. PubMed ID: 8416115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Raising awareness of new psychoactive substances: chemical analysis and in vitro toxicity screening of 'legal high' packages containing synthetic cathinones.
    Araújo AM; Valente MJ; Carvalho M; Dias da Silva D; Gaspar H; Carvalho F; de Lourdes Bastos M; Guedes de Pinho P
    Arch Toxicol; 2015 May; 89(5):757-71. PubMed ID: 24903018
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Understanding the risks associated with the use of new psychoactive substances (NPS): high variability of active ingredients concentration, mislabelled preparations, multiple psychoactive substances in single products.
    Zamengo L; Frison G; Bettin C; Sciarrone R
    Toxicol Lett; 2014 Aug; 229(1):220-8. PubMed ID: 24910986
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [New psychoactive substances and their prevalence in the Czech Republic].
    Mravčík V; Běláčková V; Grohmannová K; Zábranský T
    Cas Lek Cesk; 2015; 154(5):216-21. PubMed ID: 26612328
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Use of Psychoactive Substances and Illegal Drugs in the Albanian Society.
    Matua L; Muharremi G; Petrela E; Koçibelli M; Vyshka G; Xhemali B
    Curr Drug Res Rev; 2019; 11(1):73-79. PubMed ID: 30070180
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Deaths from novel psychoactive substances in England, Wales and Northern Ireland: Evaluating the impact of the UK psychoactive substances act 2016.
    Deen AA; Claridge H; Treble RD; Hamnett HJ; Copeland CS
    J Psychopharmacol; 2021 Nov; 35(11):1315-1323. PubMed ID: 34182812
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute recreational drug and new psychoactive substance toxicity in Europe: 12 months data collection from the European Drug Emergencies Network (Euro-DEN).
    Dines AM; Wood DM; Yates C; Heyerdahl F; Hovda KE; Giraudon I; Sedefov R; Dargan PI;
    Clin Toxicol (Phila); 2015 Nov; 53(9):893-900. PubMed ID: 26503789
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Deaths of individuals aged 16-24 years in the UK after using mephedrone.
    Loi B; Corkery JM; Claridge H; Goodair C; Chiappini S; Gimeno Clemente C; Schifano F
    Hum Psychopharmacol; 2015 Jul; 30(4):225-32. PubMed ID: 26216555
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Toxicology and management of novel psychoactive drugs.
    Kersten BP; McLaughlin ME
    J Pharm Pract; 2015 Feb; 28(1):50-65. PubMed ID: 25261428
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.